ADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation.

TitleADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation.
Publication TypeJournal Article
Year of Publication2016
AuthorsBohrer LR, Chaffee TS, Chuntova P, Brady NJ, Witschen PM, Kemp SE, Nelson AC, Walcheck B, Schwertfeger KL
JournalGenes Cancer
Volume7
Issue7-8
Pagination240-253
Date Published2016 Jul
ISSN1947-6019
Abstract

The presence of inflammatory cells within the tumor microenvironment has been tightly linked to mammary tumor formation and progression. Specifically, interactions between tumor cells and infiltrating macrophages can contribute to the generation of a pro-tumorigenic microenvironment. Understanding the complex mechanisms that drive tumor cell-macrophage cross-talk will ultimately lead to the development of approaches to prevent or treat early stage breast cancers. As described here, we demonstrate that the cell surface protease a disintegrin and metalloproteinase 17 (ADAM17) is expressed by macrophages in mammary tumors and contributes to regulating the expression of pro-inflammatory mediators, including inflammatory cytokines and the inflammatory mediator cyclooxygenase-2 (Cox-2). Furthermore, we demonstrate that ADAM17 is expressed on leukocytes, including macrophages, within polyoma middle T (PyMT)-derived mammary tumors. Genetic deletion of ADAM17 in leukocytes resulted in decreased onset of mammary tumor growth, which was associated with reduced expression of the Cox-2 within the tumor. These findings demonstrate that ADAM17 regulates key inflammatory mediators in macrophages and that leukocyte-specific ADAM17 is an important promoter of mammary tumor initiation. Understanding the mechanisms associated with early stage tumorigenesis has implications for the development of preventive and/or treatment strategies for early stage breast cancers.

DOI10.18632/genesandcancer.115
Alternate JournalGenes Cancer
PubMed ID27738494
PubMed Central IDPMC5059114
Grant ListR01 CA132827 / CA / NCI NIH HHS / United States
R01 CA215052 / CA / NCI NIH HHS / United States
R21 CA184541 / CA / NCI NIH HHS / United States
UL1 TR000114 / TR / NCATS NIH HHS / United States
Related Faculty: 
Nicholas Brady, Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700